Aims and Scope of Current Cancer Drug Targets
Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers. The editor-in-chief is Ruiwen Zhang (UH Drug Discovery Institute). The journal covers research on contemporary molecular drug targets involved in cancer, including medicinal chemistry, pharmacology, molecular biology, genomics, and biochemistry. Current Cancer Drug Targets publishes original research reports, review papers, and rapid communications ("letters"). Less
Key Metrics
CiteScore 

6.4
H-Index 

99
Impact Factor 

< 5
SJR 

Q2Oncology

SNIP 

0.85
Recommended pre-submission checks
Powered by 

Topics Covered on Current Cancer Drug Targets
Current Cancer Drug Targets Journal Specifications
| Overview | |
| Publisher | BENTHAM SCIENCE PUBL LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2000 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Current Cancer Drug Targets ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Current Cancer Drug Targets
Ectophosphatase Activity in Human Hepatocellular Carcinoma Huh7 Cells: Characterisation and Implications for the Tumour Microenvironment
- 13 May 2026
- Current Cancer Drug Targets
Research Progress on Immunotherapy Targets in Nasopharyngeal Carcinoma.
- 9 May 2026
- Current cancer drug targets
HPGD Inhibited Natural Killer Cell Activation and Enhanced Autophagy to Promote the Progression of Papillary Thyroid Cancer by Activating the JAK2/STAT3 Pathway.
- 8 May 2026
- Current cancer drug targets
Impact of ncRNAs on Immunocyte Regulation and Antitumor Immune Responses in Cancer.
- 8 May 2026
- Current cancer drug targets
Anlotinib for Advanced Peritoneal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Revie.
- 4 May 2026
- Current cancer drug targets
PCK2 Promotes Non-Small Cell Lung Cancer Progression via SLC38A2- Mediated Glutamine Uptake and mTORC1 Activation.
- 28 Apr 2026
- Current cancer drug targets
Ectophosphatase Activity in Human Hepatocellular Carcinoma Huh7 Cells: Characterisation and Implications for the Tumour Microenvironment
- 13 May 2026
- Current Cancer Drug Targets
Research Progress on Immunotherapy Targets in Nasopharyngeal Carcinoma.
- 9 May 2026
- Current cancer drug targets
HPGD Inhibited Natural Killer Cell Activation and Enhanced Autophagy to Promote the Progression of Papillary Thyroid Cancer by Activating the JAK2/STAT3 Pathway.
- 8 May 2026
- Current cancer drug targets
Impact of ncRNAs on Immunocyte Regulation and Antitumor Immune Responses in Cancer.
- 8 May 2026
- Current cancer drug targets
Anlotinib for Advanced Peritoneal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Revie.
- 4 May 2026
- Current cancer drug targets
PCK2 Promotes Non-Small Cell Lung Cancer Progression via SLC38A2- Mediated Glutamine Uptake and mTORC1 Activation.
- 28 Apr 2026
- Current cancer drug targets